 Sage Therapeutics Inc NASDAQ: SAGE and Biogen Inc NASDAQ: BIIB have announced data from WATERFALL Phase 3 study evaluating zuranolone SAGE-217BIIB125 in patients with Major Depressive Disorder MDD. The 543-subject trial met its primary endpoint with zuranolone showing statistically significant improvement in depressive symptoms compared with placebo at Day 15. 